Pfizer sues India generic drugmaker over cancer drug

Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novartis defeats Orange Book challenge but suffers EU setback

24 September 2026 An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.

Pharma

Behind the case: How Novartis defended its blockbuster Entresto in the UK

22 September 2026 After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.

Pharma

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

17 September 2026 Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.

More features

Novartis defeats Orange Book challenge but suffers EU setback

New UK High Court judge named as replacement for Justice Meade

US firm hires litigation pro whose clients include Pfizer, Medtronic

Behind the case: How Novartis defended its blockbuster Entresto in the UK

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

Benesch adds former McDermott IP practice head

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Pfizer sues India generic drugmaker over cancer drug

More on this story

Editor's picks

Editor's picks

More features